生殖系神经纤维瘤蛋白1突变增强抗肿瘤免疫反应并降低幼年型粒单核细胞白血病致瘤性
本研究探讨生殖系NF1突变单独存在时为何不直接引起幼年型粒单核细胞白血病(JMML)。通过比较JMML与NF1患者生物学特性及iPSC诱导的造血与巨噬细胞分化,发现NF1突变或敲除可促进NK细胞和iMacs增殖与免疫功能,且NF1突变iNKs能杀伤NF1敲除iMacs并延缓异种移植模型白血病进展,提示生殖系NF1突变单独不能直接驱动JMML,并提示潜在细胞免疫治疗。
要点
- 生殖系NF1突变单独存在时不能直接驱动JMML发生。
- NF1突变或敲除可促进iPSC来源NK细胞和iMacs的增殖与免疫功能。
- NF1突变iNKs可杀伤NF1敲除iMacs并延缓异种移植模型白血病进展。
核心结论
- 生殖系NF1突变单独不能直接驱动JMML发生,并提示针对JMML患者的潜在细胞免疫治疗。
研究设计与样本
- 比较JMML与NF1患者的生物学特性,并利用iPSC来源的造血与巨噬细胞分化及异种移植动物模型进行研究。
主要发现
- JMML和NF1患者均可增加单核细胞生成,但NF1患者的单核细胞不能进一步恶性进展。
- NF1突变或敲除可重现JMML经典造血病理特征,并促进iPSC来源NK细胞和iMacs的增殖与免疫功能。
- NF1突变iNKs对NF1敲除iMacs具有高杀伤能力。
- 给予NF1突变或敲除的iNKs可延缓异种移植动物模型的白血病进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Juvenile myelomonocytic leukaemia (JMML) is an aggressive paediatric leukaemia characterized by mutations in five canonical RAS pathway genes, including the NF1 gene. JMML is driven by germline NF1 gene mutations, with additional somatic aberrations resulting in the NF1 biallelic inactivation, leading to disease progression. Germline mutations in the NF1 gene alone primarily cause benign neurofibromatosis type 1 (NF1) tumours rather than malignant JMML, yet the underlying mechanism remains unclear. Here, we demonstrate that with reduced NF1 gene dose, immune cells are promoted in anti-tumour immune response. Comparing the biological properties of JMML and NF1 patients, we found that not only JMML but also NF1 patients driven by NF1 mutations could increase monocytes generation. But monocytes cannot further malignant development in NF1 patients. Utilizing haematopoietic and macrophage differentiation from iPSCs, we revealed that NF1 mutations or knockout (KO) recapitulated the classical haematopoietic pathological features of JMML with reduced NF1 gene dose. NF1 mutations or KO promoted the proliferation and immune function of NK cells and iMacs derived from iPSCs. Moreover, NF1-mutated iNKs had a high capacity to kill NF1-KO iMacs. NF1-mutated or KO iNKs administration delayed leukaemia progression in a xenograft animal model. Our findings demonstrate that germline NF1 mutations alone cannot directly drive JMML development and suggest a potential cell immunotherapy for JMML patients.
引用
- Wang W, Li X, Qin X, et al. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity. Br J Haematol. 2023. PMID: 37144690. doi:10.1111/bjh.18851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。